Genelux Corporation Common Stock

Day range

$1.81 – $1.99

Open

$1.83

Prev close

$1.82

Volume

185.1K

Market cap

$82.35M

Shares out

45.25M

P/E

—

P/S

10293.31

P/B

5.11

P/FCF

—

ROE

-220.9%

ROA

-135.8%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 5, 2026

• Underwriting agreementMar 19, 2026

  On March 19, 2026, Genelux Corporation (the "Company") entered into a Sales Agreement (the "Sales Agreement") with TD Securities (USA) LLC ("TD Cowen"), pursuant to which the Company may, from time to time, offer and sell shares of the Company's common stock, par value $0.001 per share (the "Placement Shares"), having an aggregate offering price of up to $100,000,000, through TD Cowen, acting as the Company's sales agent and/or principal.

• Investor presentationFeb 2, 2026

  On February 2, 2026, Genelux Corporation (the "Company") updated its corporate presentation (the "Corporate Presentation") with certain business and strategic updates. Information from the Corporate Presentation may be used by the management of the Company in future meetings regarding the Company and will also be available in the "Investors" section of the Company's website at investors.genelux.com.

• Underwriting agreementJan 8, 2026

  The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended (the "Securities Act"), other obligations of the parties and termination provisions.

• Clinical trial resultsJan 5, 2026

  On January 5, 2026, Genelux reported interim results from two ongoing trials evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer and progressive non-small cell lung cancer, respectively, after failure of prior platinum-based regimens. As of the data review cutoff date of December 23, 2025, systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved the following preliminary results: 9 evaluable patients, Overall response rate (ORR) of 33% (3/9 patients), including three partial responses (PRs), and Disease control rate (DCR) of 67% (6/9 patients).

• Executive officer appointmentJan 2, 2026

  On January 2, 2026, the Company announced the appointment of Jason Litten, M.D. as the Company's Chief Medical Officer, effective as of January 2, 2026. Dr. Litten, 52, most recently served as the Chief Medical Officer of Chimeric Therapeutics, Ltd. since July 2022. Dr. Litten is an expert in clinical oncology with experience developing numerous therapeutics modalities.

Days to cover

15.7

Short interest

4.64M

Avg volume

295.51K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
  neutralGlobeNewswire Inc.· Jan 12, 2026
• Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
  positiveGlobeNewswire Inc.· Jan 2, 2026
• Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
  positiveGlobeNewswire Inc.· Sep 3, 2024
• Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
  positiveGlobeNewswire Inc.· Jul 30, 2024
• Unveiling 4 Analyst Insights On Genelux
  Benzinga· May 31, 2024